Wangyu Zhu
Overview
Explore the profile of Wangyu Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
583
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu W, Yang W, Sun G, Huang J
Ann Med
. 2024 Dec;
57(1):2443046.
PMID: 39711373
Background: Quaking (QKI) is a member of the signal transduction and activators of RNA (STAR) family, performing a crucial multifunctional regulatory role in alternative splicing, mRNA precursor processing, mRNA transport...
2.
Fang J, Li H, Zhu W, Xie B
RSC Adv
. 2024 Oct;
14(46):34320-34327.
PMID: 39473795
Superparamagnetic iron oxide nanoparticles (SPIONs) find vast applications in biomedicine such as drug delivery, magnetic resonance imaging (MRI) contrast agents, cell separation, tissue repair, The synthesis of pure and uniform...
3.
Zhu W, Zhang H, Tang L, Fang K, Lin N, Huang Y, et al.
Clin Respir J
. 2024 Oct;
18(10):e70026.
PMID: 39428538
Background: Exosomes have been established to be enriched with various long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) that exert various biological effects. However, the lncRNA- and circRNA-mediated coexpression competing...
4.
Wu S, Zhao Q, Liu S, Kuang J, Zhang J, Onga A, et al.
Int J Oncol
. 2024 Jun;
65(2).
PMID: 38873997
Non‑small cell lung cancer (NSCLC) is one of the major causes of cancer‑related death worldwide. Cisplatin is a front‑line chemotherapeutic agent in NSCLC. Nevertheless, subsequent harsh side effects and drug...
5.
Ni L, Zhu X, Zhao Q, Shen Y, Tao L, Zhang J, et al.
Neoplasia
. 2024 Mar;
51:100991.
PMID: 38507887
Dihydroartemisinin (DHA) exerts an anti-tumor effect in multiple cancers, however, the molecular mechanism of DHA and whether DHA facilitates the anti-tumor efficacy of cisplatin in non-small cell lung cancer (NSCLC)...
6.
Zhu W, Yu Y, Ye Y, Tu X, Zhang Y, Wu T, et al.
Transl Oncol
. 2023 Aug;
37:101755.
PMID: 37595393
Background: Our recent study found that QKI-5 regulated miRNA, miR-196b-5p, promotes non-small cell lung cancer (NSCLC) progression by directly targeting GATA6, TSPAN12 and FAS. However, the biological functions of miR-196b-5p...
7.
Zhu W, Yu Y, Fang K, Xiao S, Ni L, Yin C, et al.
Cancer Med
. 2022 Sep;
12(4):4590-4604.
PMID: 36172919
Background: RNA-binding protein Quaking-5 (QKI-5), a major isoform of QKIs, inhibits tumor progression in non-small cell lung cancer (NSCLC). However, the underlying molecular mechanisms of QKI-5 in the cell cycle...
8.
Zhu W, Qiu X, Lin N, Fang K, Zhang T, Ishii N, et al.
Ann Transl Med
. 2022 Jun;
10(10):585.
PMID: 35722397
Background: The lymph node ratio (LNR) is an additional informative factor complementing anatomic TNM staging in breast cancer patients. The aim of this study was to evaluate the role of...
9.
Li H, Li L, Zheng H, Xiao M, Wang Q, Li S, et al.
Ann Palliat Med
. 2022 Jan;
10(12):12810-12820.
PMID: 35016431
Background: We aimed to identify any differences in the clinical characteristics of patients treated in Zhoushan Hospital and Wuhan Fourth Hospital, Gutian campus to provide insights into measures to better...
10.
Huang X, Zhu X, Yu Y, Zhu W, Jin L, Zhang X, et al.
Cancer Lett
. 2021 Jan;
501:66-82.
PMID: 33385486
Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer related deaths worldwide. Despite recent advancements in surgical and molecular targeted therapies that improved the therapeutic...